Arthroscopic Synovectomy of the Wrist in Inflammatory Arthritis

NCT04755127 | Unknown DMC

• 1 other identifier: ARCTIC01
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

Rationale: Psoriatic (PsA) and rheumatoid arthritis (RA) are inflammatory joint diseases that often involve the wrist and may result in progressive joint destruction followed by impaired wrist function and reduced quality of life. The first line treatment usually consists of conventional Disease-Modifying Anti-Rheumatic Drugs (cDMARDs) along with bridging therapy using systemic corticosteroids or intra-articular corticosteroids in case of limited joint disease. After initiation therapy, intra-articular corticosteroids are often utilized as they provide rapid dampening of joint inflammation in case of a flare-up of disease activity (mono- or oligoarthritis). However, a substantial part of these patients clinically respond poorly or not at all. Alternatively, arthroscopic synovectomy may provide substantial relieve of symptoms, improve functionality, slow down disease progression and prevent joint destruction, as earlier studies have suggested. Prospective randomized studies are needed to confirm these findings. Moreover, they may prevent the need for expensive biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) and assist in guiding therapeutic strategies in the long run, through collecting and analysing valuable synovial biopsies. Wrist arthroscopy is a routine procedure in the participating centres with only minor complications and fast recovery. Objective: To compare arthroscopic synovectomy with deposition of intra-articular corticosteroids (DIACS) versus intra-articular injection of corticosteroids (IACSI) in RA and PsA patients with mono- or oligoarthritis of the wrist that is refractory to cDMARD therapy. Study design: Multi-centre randomized controlled trial conducted in the Maasstad Hospital and Spijkenisse Medisch Centrum (SMC). Study population: Patients with active RA or PsA and bDMARD-naive, who develop a localized flare of disease activity (mono- or oligoarthritis) that involves the wrist, defined as an increase in DAS28 \> 1.2 or \> 0.6 if DAS28 ≥ 3.2 compared to the last DAS28 measurement (maximum six months before) and that is refractory to systemic cDMARD for at least three months, defined as no response on the European League Against Rheumatism (EULAR) response criteria. Intervention: This study will randomize between IACSI of the wrist (control) and arthroscopic synovectomy of the wrist combined with DIACS (intervention). During arthroscopy synovial biopsies will be collected and stored for later analysis of the functional and histological characteristics of the synovium (beyond the scope of this study). Main study parameters/endpoints: Primary outcome is the change in Patient-Rated Wrist Evaluation (PRWE) score from randomization to three months of follow-up. The PRWE is a validated, fifteen-item self-reported questionnaire rating wrist pain and function. Secondary outcomes are resolution of wrist arthritis measured by ultrasound, standard wrist radiographs, DAS28, EULAR response rate, Visual Analogue Scale (VAS), EQ-5D quality of life questionnaire, iMTA Productivity Cost Questionnaire (iPCQ), iMTA Medical Consumption Questionnaire (iMCQ), cost effectiveness analyses (CEA), physical examination, adverse events (AE) and laboratory results. Follow-up visits are scheduled at three, six and twelve months after intervention. Nature and extent of the burden and risks associated with study participation: Both study arms include standard treatment of care. Wrist arthroscopy is a standard treatment for wrist arthritis and often implemented for other intra-articular wrist pathology. The risks include infection, neurovascular damage and articular surface damage. Nevertheless, wrist arthroscopy is a well-established and safe technique. Reduction of risks will be done according to inclusion and exclusion criteria. If complications arise, the treating physician will proportionate the adequate treatment according to the current protocols based on the published literature. Patients will be asked to return at three, six and twelve months. These visits are standard of care following the rheumatic arthritis protocol. Patients will be asked to complete questionnaires at baseline and at three follow-up moments. These will take 160 minutes in total. The arthroscopy group will return between ten to fourteen days for wound inspection. All patient will be contacted by telephone at two, four and six weeks for VAS pain scores. Expected results: We expect that arthroscopic synovectomy followed by DIACS will lead to significantly more improvement in PRWE scores compared to IACSI three months after intervention. Furthermore, we anticipate that wrist arthroscopy will result in lower pain scores, better joint mobility, better response on EULAR score, sustained resolution of arthritis on ultrasound, less joint damage on radiographs and is more cost-effective after one-year analysis.

Conditions

Wrist Arthritis; Psoriatic Arthritis; Rheumatoid Arthritis; Surgery

Keywords

Wrist arthroscopy; Arthroscopic synovectomy; Rheumatoid arthritis; Psoriatic Arthritis; Patient related outcome

Outcome Measures

Primary Outcomes (1)

• Patient-Rated Wrist evaluation (PRWE)

  15-item questionnaire scoring pain and wrist function on a scale from 0-100, with a higher score indicating worse outcome.

  3 months

Secondary Outcomes (13)

• Patient-Rated Wrist evaluation (PRWE)

  6 and 12 months

• Wrist ultrasound

  3 months

• Wrist X-ray

  12 months

• NRS pain score

  2, 4 and 6 weeks, 3, 6 and 12 months

• Range of motion

  3, 6 and 12 months

Study Arms (2)

Intra-articular corticosteroid injection

ACTIVE COMPARATOR

Injection with 40mg triamcinolone acetonide (kenacort) in the wrist

Drug: Intra-articular corticosteroid injection

arthroscopic synovectomy

EXPERIMENTAL

Wrist arthroscopy in day surgery setting with debulking of synovitis, inspection of cartilage, ligament, tendon and bone damage, collection of synovial biopsies and deposition of intra-articular corticosteroids (40mg triamcinolone acetonide)

Procedure: Arthroscopic synovectomy of the wrist

Interventions

Arthroscopic synovectomy of the wrist PROCEDURE

Wrist arthroscopy in day surgery setting with debulking of synovitis, inspection of cartilage, ligament, tendon and bone damage, collection of synovial biopsies and deposition of intra-articular corticosteroids (40mg triamcinolone acetonide)

arthroscopic synovectomy

Intra-articular corticosteroid injection DRUG

Injection with 40mg triamcinolone acetonide (kenacort) in the wrist

Intra-articular corticosteroid injection

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female patients with age ≥ 18 years
• Subjects able and willing to give written informed consent (or legally acceptable representative or impartial witness when applicable) and is available for entire study
• Patients meet the criteria of either group below:
• Patients that are diagnosed with RA according to the revised 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Rheumatoid Arthritis Classification Criteria (table 1)
• Patients are experiencing an exacerbation defined as an increase in DAS28 \> 1.2 or \> 0.6 if DAS28 ≥ 3.2 compared to last DAS28 measurement (maximum six months before)
• The exacerbation is refractory to systemic cDMARDs for at least three months, defined as 'no response' according to the EULAR response criteria (table 2)
• Wrist arthritis, that is diagnosed clinically, is the predominant symptom
• Patients that are diagnosed with PsA according to the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria (table 3)
• Patients are experiencing an exacerbation defined as an increase in DAS28 \> 1.2 or \> 0.6 if DAS28 ≥ 3.2 compared to last DAS28 measurement (maximum six months before)
• The exacerbation is refractory to systemic cDMARDs for at least three months, defined as 'no response' according to the EULAR response criteria (table 2)
• Wrist arthritis, that is diagnosed clinically, is the predominant symptom

You may not qualify if:

• Previous or current treatment with biological (b) DMARDs
• Current inflammatory joint disease other than RA or PsA (e.g. gout, reactive arthritis, Lyme disease)
• Subjects who are pregnant or intend to become pregnant during the study
• Intra-articular corticosteroids injection in the wrist in the last 6 months
• Previous wrist surgery
• Severe osteoarthritis with malformations of the wrist
• Congenital abnormalities of wrist function or motion

Sponsors & Collaborators

• Maasstad Hospital: lead

Study Sites (1)

Maasstad Hospital

Rotterdam, South Holland, 3079 DZ, Netherlands

RECRUITING

MeSH Terms

Conditions

Arthritis, Psoriatic; Arthritis, Rheumatoid

Interventions

Adrenal Cortex Hormones

Condition Hierarchy (Ancestors)

Spondylarthropathies; Spondylarthritis; Spondylitis; Spinal Diseases; Bone Diseases; Musculoskeletal Diseases; Arthritis; Joint Diseases; Psoriasis; Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases; Rheumatic Diseases; Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Intervention Hierarchy (Ancestors)

Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists

Study Officials

• Radjesh Bisoendial, MD, PhD

  Maasstad ziekenhuis

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Philip d'Ailly, MD

CONTACT

31102912205; daillyp@maastadziekenhuis.nl

Christel Deugd-Verburg, MSc

CONTACT

31102912205; DeugdC@maasstadziekenhuis.nl

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: non-blinded randomized controlled trial

Study Record Dates

• First Submitted: January 27, 2021
• First Posted: February 15, 2021
• Study Start: January 1, 2021
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: December 28, 2023

Record last verified: 2023-12

Locations

NL (1)